Showing results (81-90 of 98) with videos related to
Sort By:
Pageof 10
Journal of Medicinal Chemistry|May 16, 2025
Discovery of a New and Selective HPK1 PROTAC for Enhancing Tumor Immunotherapy through Eliminating GLK DegradationMingfei Wu, Xinfei Mao, Yiquan Wu, et al.Journal of Medicinal Chemistry|December 6, 2024
Discovery of a Novel Non-invasive AR PROTAC Degrader for the Topical Treatment of Androgenetic AlopeciaXinfei Mao, Weitong Hu, Mingfei Wu, et al.Journal of the American Chemical Society|January 10, 2026
Stability and Degradation-based Proteome Profiling Reveals Cannabidiol as a Promising CDC123-eIF2γ Inhibitor for Colorectal Cancer TherapyHengyuan Yu, Yang Chen, Mingfei Wu, et al.Nucleic Acids Research|October 13, 2023
ADCdb: the database of antibody-drug conjugatesLiteng Shen, Xiuna Sun, Zhen Chen, et al.Journal of Medicinal Chemistry|July 13, 2019
Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based DesignXiaowu Dong, Wenhu Zhan, Mengting Zhao, et al.European Journal of Medicinal Chemistry|November 4, 2024
Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemiaJingyu Zhang, Haiting Duan, Renzhao Gui, et al.Bioorganic Chemistry|January 24, 2025
Development of novel epoxyketone macrocyclic peptidyl proteasome inhibitors through OPA-mediated one-step cyclization of unprotected peptidesGongruixue Zeng, Gaoya Xu, Lixin Gao, et al.Bioorganic & Medicinal Chemistry|November 5, 2024
Exploration of novel 20S proteasome activators featuring anthraquinone structures and their application in hypoxic cardiomyocyte protectionQian Yu, Lixin Gao, Linhao Xu, et al.Bioorganic Chemistry|November 12, 2023
Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancerYiquan Wu, Mingfei Wu, Xiaoli Zheng, et al.Acta Pharmaceutica Sinica. B|January 1, 2026
Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapyYu Guo, Yi Song, Hanlin Wang, et al.Pageof 10